SECOND AMENDMENT TO DRUG DISCOVERY AND DEVELOPMENT AGREEMENTDrug Discovery and Development Agreement • May 3rd, 2012 • Array Biopharma Inc • Pharmaceutical preparations
THIS SECOND AMENDMENT TO DRUG DISCOVERY AND DEVELOPMENT AGREEMENT (“Amendment”), effective as of January 8, 2012 (the “Amendment Date”), is entered into by and between Celgene Corporation, a Delaware corporation, having a principal place of business 86 Morris Avenue, Summit, NJ 07901 (“Celgene”), and Array BioPharma Inc., a Delaware corporation, having a principal place of business at 3200 Walnut Street, Boulder, Colorado 80301 (“Array”). Celgene and Array are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” Capitalized terms used but not defined herein have the meaning assigned to them in the Agreement (as defined below).
THIRD AMENDMENT TO DRUG DISCOVERY AND DEVELOPMENT AGREEMENTDrug Discovery and Development Agreement • February 6th, 2013 • Array Biopharma Inc • Pharmaceutical preparations
THIS THIRD AMENDMENT TO DRUG DISCOVERY AND DEVELOPMENT AGREEMENT (“Amendment”), effective as of November 29, 2012 (the “Amendment Date”), is entered into by and between Celgene Corporation, a Delaware corporation, having a principal place of business 86 Morris Avenue, Summit, NJ 07901 (“Celgene”), and Array BioPharma Inc., a Delaware corporation, having a principal place of business at 3200 Walnut Street, Boulder, Colorado 80301 (“Array”). Celgene and Array are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” Capitalized terms used but not defined herein have the meaning assigned to them in the Agreement (as defined below).
PsychoGenics and Roche Enter Agreement to Identify New Treatments for Neuropsychiatric DisordersDrug Discovery and Development Agreement • May 26th, 2008
The agreement provides that Roche will provide drug candidates and PsychoGenics will evaluate these candidates, using its proprietary drug discovery technologies, for the treatment of neuropsychiatric disorders. Either party has the option to exclusively develop any drug candidate emerging from this collaboration, with the non-developing party receiving milestones and royalties commensurate with the stage of development.
DRUG DISCOVERY AND DEVELOPMENT AGREEMENTDrug Discovery and Development Agreement • November 6th, 2007 • Array Biopharma Inc • Pharmaceutical preparations • New York
THIS DRUG DISCOVERY AND DEVELOPMENT AGREEMENT (the “Agreement”) is made effective as of September 21, 2007 (“Effective Date”) by and between Array BioPharma Inc., a Delaware corporation, having its principal offices located at 3200 Walnut, Boulder, CO 80301 (“Array”), and Celgene Corporation, a Delaware corporation, having its principal offices located at 86 Morris Avenue, Summit, NJ 07901 (“Celgene”).
FIRST AMENDMENT TO DRUG DISCOVERY AND DEVELOPMENT AGREEMENTDrug Discovery and Development Agreement • August 18th, 2009 • Array Biopharma Inc • Pharmaceutical preparations • New York
THIS FIRST AMENDMENT TO DRUG DISCOVERY AND DEVELOPMENT AGREEMENT (“Amendment”), effective as of June 17, 2009 (the “Amendment Date”), is entered into by and between Celgene Corporation, a Delaware corporation, having a principal place of business 86 Morris Avenue, Summit, NJ 07901 (“Celgene”), and Array BioPharma Inc., a Delaware corporation, having a principal place of business at 3200 Walnut Street, Boulder, Colorado 80301 (“Array”). Celgene and Array are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” Capitalized terms used but not defined herein have the meaning assigned to them in the Agreement (as defined below).
PsychoGenics and AstraZeneca Enter Agreement to Identify New Treatments for Central Nervous System DisordersDrug Discovery and Development Agreement • August 28th, 2009
Under the agreement, PsychoGenics will use its proprietary drug discovery technologies to evaluate a number of AstraZeneca drug candidates for their potential to treat psychiatric disorders. PsychoGenics will receive research payments and milestones commensurate with the stage of development, as well as royalties on any future sales.
